InsidersTradesSigma
Follow the 智翔金泰 share price and the full management transaction log of the company, a listed equity based in China. Shares are listed on the CN market, under the authority of SSE / SZSE (CSRC). Operating in the Health Care sector, 智翔金泰 has logged 2 insider filings. Market capitalisation: €8.5bn. The latest transaction was reported on 8 January 2024 (Purchase). Among the most active insiders: 蒋仁生. Every trade is openly available.
2
Insider Decl.
n/a
Thresholds
€456,592
2 ops.
Buy Volume
n/a
n/a
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,722 of 28,803 companies
37.0
score / 100
Value21
Quality53
FCF yld-5.0%
Earn yld-6.3%
EV/EBITDA·
ROE-33%
Gross mgn93%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 January 2024
About 智翔金泰
智翔金泰 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHG market. It focuses on the development and commercialization of innovative pharmaceutical products.